Latest news with #TevaPharmaceuticalIndustries
Yahoo
11-08-2025
- Business
- Yahoo
Following a 4.2% decline over last year, recent gains may please Teva Pharmaceutical Industries Limited (NYSE:TEVA) institutional owners
Explore Teva Pharmaceutical Industries's Fair Values from the Community and select yours Key Insights Significantly high institutional ownership implies Teva Pharmaceutical Industries' stock price is sensitive to their trading actions A total of 18 investors have a majority stake in the company with 51% ownership Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If you want to know who really controls Teva Pharmaceutical Industries Limited (NYSE:TEVA), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 78% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Institutional investors would probably welcome last week's 4.3% increase in the share price after a year of 4.2% losses as a sign that returns may to begin trending higher. Let's take a closer look to see what the different types of shareholders can tell us about Teva Pharmaceutical Industries. Check out our latest analysis for Teva Pharmaceutical Industries What Does The Institutional Ownership Tell Us About Teva Pharmaceutical Industries? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. Teva Pharmaceutical Industries already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Teva Pharmaceutical Industries' historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Hedge funds don't have many shares in Teva Pharmaceutical Industries. Phoenix Investments & Finances Ltd is currently the largest shareholder, with 5.0% of shares outstanding. With 4.9% and 4.6% of the shares outstanding respectively, FMR LLC and BlackRock, Inc. are the second and third largest shareholders. After doing some more digging, we found that the top 18 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Insider Ownership Of Teva Pharmaceutical Industries While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our most recent data indicates that insiders own less than 1% of Teva Pharmaceutical Industries Limited. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own US$78m worth of shares. It is good to see board members owning shares, but it might be worth checking if those insiders have been buying. General Public Ownership With a 22% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Teva Pharmaceutical Industries. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Teva Pharmaceutical Industries better, we need to consider many other factors. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Reuters
30-07-2025
- Business
- Reuters
Teva Pharm's second-quarter profit boosted by branded drugs, US tariff questions remain
JERUSALEM, July 30 (Reuters) - Teva Pharmaceutical Industries ( opens new tab reported a better than expected increase in second-quarter profit on Wednesday, helped by a 26% rise in sales of its branded drugs and said it was well positioned to mitigate potential U.S. tariffs. Richard Francis, CEO of Teva, the world's largest generic drugmaker, said there was "big ambiguity" and "so many unanswered questions" in the pharmaceuticals sector regarding potential U.S. import levies. He added, however, that the Israel-based company, had been leveraging its U.S.-based manufacturing facilities and its minimal reliance upon China and India to soften the blow from any eventual tariffs. "Those aspects just set us up in the face of this change, probably a lot better than our competitors," Francis told Reuters. "I feel we have the ability to put ourselves in a good position here, with the caveat - I need to know the details." U.S. President Donald Trump initially threatened Israel with a 17% import tariff on its exports to the United States. But what will happen after his August 1 deadline expires remains unclear. Global drugmakers also face the possibility of a sector-specific U.S. tariff on pharmaceuticals despite some drug shortages in the United States. Teva said it earned 66 cents per diluted share, excluding one-time items, in the April-June quarter, up from 61 cents a share a year earlier. Revenue was flat in dollar terms at $4.18 billion. Analysts had forecast earnings of 62 cents per share ex-items for the Israel-based company on revenue of $4.28 billion, LSEG I/B/E/S data showed. Teva largely reaffirmed its 2025 estimates but revised its adjusted EPS forecast to $2.50-$2.65 from $2.45-$2.65. It still projects revenue of $16.8 billion to $17.2 billion this year and said it was on track for 30% operating profit margin by 2027. After a strong 2024, generic drugs were largely flat globally in the quarter, falling in the United States but offset by gains in Europe. Among its branded drugs, sales of its Huntington's Disease treatment Austedo grew 19% to $498 million, while migraine medicine Ajovy rose 31% to $155 million and Uzedy, a drug to treat schizophrenia, jumped 120% to $54 million. As a result, Teva raised its estimate for 2025 sales of Austedo slightly to $2 billion to $2.05 billion. It sees sales of Ajovy at $630 million to $640 million and Uzedy at $190 million to $200 million. It added it would double biosimilar revenues from 2024 to 2027 and said it remained in negotiations to sell its active pharmaceutical ingredients unit. Teva, Francis noted, has a large pipeline of drugs that will be launched in the coming decade - starting with schizophrenia drug Olanzapine in the fourth quarter - that combined will likely peak at more than $10 billion in sales. Its New York-listed shares were up 2.9% at $17.15 in mid-morning trade.
Yahoo
10-07-2025
- Business
- Yahoo
Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders
Bold speculators interested in a quick strike may want to set their sights on healthcare specialist Teva Pharmaceutical Industries (TEVA). But rather than a long discussion on fundamental items that are essentially summaries of yesterday's newspaper, I'd like to begin the discussion about TEVA stock with a thought experiment. Imagine that you flip a (fair) coin 100 times every business day. What you flip on Monday would have no bearing on what you flip on Tuesday and so forth. Obviously, coin tosses represent random events. If your job was to determine the likelihood of a higher ratio of heads versus tails on Friday, knowing what the 'score' was on the previous day would offer no useful intelligence. Delta Air Lines Shows Unusual Call Options Ahead of Earnings - Investors are Bullish on DAL Stock Covered Call Screener Results For July 9th Creating a 38% 'Dividend' on SOFI Stock Using Options Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Now imagine that the stock market is random. If investors were net buyers of a security on Monday, this fact would have no bearing on the stock's performance on Tuesday. It would also mean that analysts could pull up historical price data and check the performance of the security across multiple time intervals. In a random ecosystem, the long-side success ratio for all these intervals would hover around 50%. Instinctively, we understand that this null hypothesis isn't valid: otherwise, why bother with the financial publication industry? The point of this sector is to decipher the statistical landscape of the security at hand and act only when the odds favor the speculator. Over the past few months, I've personally drifted away from fundamental and technical analysis, in large part because these methodologies seek to extract forward probabilities based on vibes and stuff. Instead, we should extract the probabilities using math. Applying statistical analysis on a publicly traded enterprise is conceptually a difficult concept because of the non-stationary problem. Essentially, the share price rarely stays localized in a narrow range. Instead, it moves, often wildly. For example, TEVA stock has more than doubled in value since late October 2023. This makes probabilistic analysis based on the use of past analogs rather challenging. To get around this problem, we can apply discretization; that is, convert price action into discrete events. For this purpose, market breadth — or sequences of accumulative and distributive sessions — represents a viable solution. As a representation of demand, market breadth is effectively binary as investors are either net buyers or net sellers during a particular session. From here, individual market profiles can be segregated into distinct behavioral states. If we convert TEVA stock's historical price data (across 10-week intervals) since January 2019 into market breadth, we get the below summation: Ticker L10 Category Sample Size Up Probability Baseline Probability Delta Median Return if Up TEVA 1-9-D 9 44.44% 49.71% -5.27% 7.66% TEVA 2-8-D 10 10.00% 49.71% -39.71% 3.05% TEVA 3-7-D 13 69.23% 49.71% 19.52% 3.34% TEVA 3-7-U 1 0.00% 49.71% -49.71% N/A TEVA 4-6-D 51 60.78% 49.71% 11.07% 4.70% TEVA 4-6-U 19 52.63% 49.71% 2.92% 3.94% TEVA 5-5-D 46 39.13% 49.71% -10.58% 2.62% TEVA 5-5-U 38 52.63% 49.71% 2.92% 4.22% TEVA 6-4-D 13 53.85% 49.71% 4.14% 3.21% TEVA 6-4-U 50 48.00% 49.71% -1.71% 3.52% TEVA 7-3-D 3 100.00% 49.71% 50.29% 8.55% TEVA 7-3-U 21 47.62% 49.71% -2.09% 2.09% TEVA 8-2-U 16 56.25% 49.71% 6.54% 1.77% TEVA 9-1-U 6 50.00% 49.71% 0.29% 4.24% Currently, TEVA stock is printing a 4-6-D sequence: four up weeks, six down weeks, with a negative trajectory across the 10-week period. What's significant about this sequence is that, in 60.78% of cases, the following week's price action results in upside, with a median return of 4.7%. While this statistical profile doesn't guarantee upside success, what it does is establish guideposts to help the decision-making process. Traders may thus treat TEVA stock like a game of blackjack. Certain hands or sequences aren't favorable to the bullish speculator so they may hold off. However, the 4-6-D sequence is statistically favorable, making a debit-based wager enticing. Also, if the market were truly random, all these sequences would share roughly the same probability — around 50%. They don't. Some sequences clearly favor long-side speculation, which is why TEVA stock is tempting. Using the market intelligence above, speculators who want to roll the dice may consider the 17/17.50 bull call spread expiring July 18. This transaction involves buying the $17 call and simultaneously selling the $17.50 call, for a net debit paid of $15 (the most that can be lost in the trade). Should TEVA stock rise through the short strike price ($17.50) at expiration, the maximum reward is $35 or a payout of over 233%. Admittedly, this is a tight time window. For those who want an extra week, they may consider the 16.50/18 bull spread expiring July 25. However, the short strike price jumps from $17.50 to $18, which is almost a 3% difference. That's something to keep in mind because it's quite a steep price in exchange for the time cushion. Either way, the probabilistic principle undergirding the above trades is this: as a baseline, TEVA stock has a slightly negative bias so the 4-6-U sequence incentivizes a bullish posture. Specifically, a random long position has a 49.56% chance of being profitable over a one-week period. However, the aforementioned sequence tilts the odds in favor of the bull, thus warranting consideration. On the date of publication, Josh Enomoto did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
02-06-2025
- Health
- Business Insider
Teva announces results from a study of treatment patterns of tardive dyskinesia
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced results from a study of treatment patterns among patients with tardive dyskinesia residing in long-term care facilities, highlighting a critical gap in TD diagnosis and treatment. Key results from the study revealed: Of the residents being treated with antipsychotic drugs, 5.6% had a diagnosis of extrapyramidal syndrome, – a broad term used to describe any drug-induced movement disorder with no wide-treating therapeutic option – while 1.1% had a specific diagnosis of TD. The most common comorbidities observed in residents on APDs at risk for TD included dementia, chronic pulmonary disease and congestive heart failure. Moderate or severe liver disease was observed in less than1% of residents on APDs. Less than half of patients diagnosed with TD residing in LTC settings received the standard of care treatment recommended by the American Psychiatric Association – a vesicular monoamine transporter 2 inhibitor. The majority were treated with a non-FDA approved treatment, primarily benztropine, and a quarter were not treated at all. Confident Investing Starts Here:
Yahoo
13-05-2025
- Business
- Yahoo
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
A recommendation upgrade from a veteran investment bank put some real zip in the shares. The analyst behind the change is now bullish on Teva's future. 10 stocks we like better than Teva Pharmaceutical Industries › A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (NYSE: TEVA) well higher on Monday. The company, known for being a top producer of generic drugs, saw its share price swell almost 6% as a result. That was good enough to beat even the very frothy S&P 500's (SNPINDEX: ^GSPC) 3.3% gain that trading session. The person behind the modification was JPMorgan Chase analyst Chris Schott, who pushed up his Teva stock recommendation one notch from neutral to overweight (read: buy). He also bumped his price target higher, from $21 per share to $23. The new level anticipates upside of 28% on the most recent closing stock price. According to reports, much of Schott's new analysis of Teva centers on the cost-cutting measures the company announced recently. In his opinion, the $700 million initiative makes management's goal of reaching a 30% operating margin by 2027 achievable. At the same time, it should also provide sufficient room for the company to keep its pipeline programs funded. Past that year, the prognosticator is bullish on Teva's branded products. In his estimation, drugs like Austedo, Olanzapine, and Duvakitug could drive the company's growth well higher. For the most part, the clutch of analysts tracking Teva are also expecting improvement in key fundamentals. Collectively, they feel full-year 2025 revenue will tick up by almost 3% this year over 2024 to $17 billion, with per-share net income improving at just under 2%. And although 2026 revenue is forecast to creep less than 1% higher year over year, that per-share net income figure should rise by a robust 9%. To me, Teva has quite a strong position as a crucial manufacturer of generic drugs. Yet it certainly isn't neglecting the branded side of its business, which is showing promise these days. I also like how management has assertively cleaned the balance sheet. Therefore, I don't blame Schott for being more bullish on Teva's future. Before you buy stock in Teva Pharmaceutical Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Teva Pharmaceutical Industries wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $614,911!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $714,958!* Now, it's worth noting Stock Advisor's total average return is 907% — a market-crushing outperformance compared to 163% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy. Why Teva Pharmaceuticals Stock Blasted 6% Higher Today was originally published by The Motley Fool
